Whipple's disease epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
Line 32: Line 32:
*The majority of Whipple's disease cases are reported in North America and western Europe.<ref name="FenollarPuéchal2007">{{cite journal|last1=Fenollar|first1=Florence|last2=Puéchal|first2=Xavier|last3=Raoult|first3=Didier|title=Whipple's Disease|journal=New England Journal of Medicine|volume=356|issue=1|year=2007|pages=55–66|issn=0028-4793|doi=10.1056/NEJMra062477}}</ref>
*The majority of Whipple's disease cases are reported in North America and western Europe.<ref name="FenollarPuéchal2007">{{cite journal|last1=Fenollar|first1=Florence|last2=Puéchal|first2=Xavier|last3=Raoult|first3=Didier|title=Whipple's Disease|journal=New England Journal of Medicine|volume=356|issue=1|year=2007|pages=55–66|issn=0028-4793|doi=10.1056/NEJMra062477}}</ref>


=== Developed Countries ===
* In Europe, the prevalence of chronic carrier of Tropheryma whipplei is 1%-11% of general adult population.<ref name="FenollarLaouira2008">{{cite journal|last1=Fenollar|first1=Florence|last2=Laouira|first2=Sonia|last3=Lepidi|first3=Hubert|last4=Rolain|first4=Jean‐Marc|last5=Raoult|first5=Didier|title=Value ofTropheryma whippleiQuantitative Polymerase Chain Reaction Assay for the Diagnosis of Whipple Disease: Usefulness of Saliva and Stool Specimens for First‐Line Screening|journal=Clinical Infectious Diseases|volume=47|issue=5|year=2008|pages=659–667|issn=1058-4838|doi=10.1086/590559}}</ref><ref name="FenollarTrani2008">{{cite journal|last1=Fenollar|first1=Florence|last2=Trani|first2=Michèle|last3=Davoust|first3=Bernard|last4=Salle|first4=Bettina|last5=Birg|first5=Marie‐Laure|last6=Rolain|first6=Jean‐Marc|last7=Raoult|first7=Didier|title=Prevalence of AsymptomaticTropheryma whippleiCarriage among Humans and Nonhuman Primates|journal=The Journal of Infectious Diseases|volume=197|issue=6|year=2008|pages=880–887|issn=0022-1899|doi=10.1086/528693}}</ref>
=== Developing Countries ===
=== Developing Countries ===
* In Senegal, the prevalence of chronic carrier of [[Tropheryma whipplei]] is 75% of children under 4 years of age.<ref name="KeitaRaoult2013">{{cite journal|last1=Keita|first1=Alpha Kabinet|last2=Raoult|first2=Didier|last3=Fenollar|first3=Florence|title=Tropheryma whippleias a commensal bacterium|journal=Future Microbiology|volume=8|issue=1|year=2013|pages=57–71|issn=1746-0913|doi=10.2217/fmb.12.124}}</ref>
* In Senegal, the prevalence of chronic carrier of [[Tropheryma whipplei]] is 75% of children under 4 years of age.<ref name="KeitaRaoult2013">{{cite journal|last1=Keita|first1=Alpha Kabinet|last2=Raoult|first2=Didier|last3=Fenollar|first3=Florence|title=Tropheryma whippleias a commensal bacterium|journal=Future Microbiology|volume=8|issue=1|year=2013|pages=57–71|issn=1746-0913|doi=10.2217/fmb.12.124}}</ref>

Revision as of 15:18, 1 November 2017

Whipple's disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Whipple's disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Whipple's disease epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Whipple's disease epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Whipple's disease epidemiology and demographics

CDC on Whipple's disease epidemiology and demographics

Whipple's disease epidemiology and demographics in the news

Blogs on Whipple's disease epidemiology and demographics

Directions to Hospitals Treating Whipple's disease

Risk calculators and risk factors for Whipple's disease epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]

Overview

Whipple's disease is an extremely rare disease among middle-aged white males in North America and western Europe. It affects males 8 times more than females. Few studies were done to evaluate the demographics of Whipple's disease due to sparsity of the disease. It is a fatal disease, if left untreated. 

Epidemiology and Demographics

Incidence

  • The incidence of Whipple's disease is approximately 12 annually worldwide.[1]
  • Between 1907 and 1987, the incidence of Whipple's disease was estimated to be 696 cases worldwide.[1]
  • The incidence of Whipple's disease is approximately 1 per 1,000,000 individuals annually in north-western Italy.[2]

Prevalence

  • The prevalence of Whipple's disease is approximately 3 per 1,000,000 individuals in north-western Italy.[2]

Case-fatality rate

  • The case-fatality rate of Whipple's disease is approximately 100%, if left untreated.[3]
  • The case-fatality rate of treated Whipple's disease is unknown.[4]

Age

  • Whipple's disease commonly affects individuals between 40 to 60 years of age; the median age at diagnosis is 50 years.[5]

Race

  • Whipple's disease usually affects individuals of the caucasian race. Africans and Asians are less likely to develop Whipple's disease.[6]

Gender

  • Males are more commonly affected by Whipple's disease than females. The male to female ratio is approximately 8 to 1.[5]

Region

  • The majority of Whipple's disease cases are reported in North America and western Europe.[7]

Developed Countries

  • In Europe, the prevalence of chronic carrier of Tropheryma whipplei is 1%-11% of general adult population.[8][9]

Developing Countries

  • In Senegal, the prevalence of chronic carrier of Tropheryma whipplei is 75% of children under 4 years of age.[10]
  • In Laos, the prevalence of chronic carrier of Tropheryma whipplei is 48% by using quantitative real-time PCR (qPCR) of the feces of children.[11]
  • In Ghana, the prevalence of chronic carrier of Tropheryma whipplei is 27.5% by using quantitative real-time PCR (qPCR) of the feces of children.[12]

References

  1. 1.0 1.1 Dobbins W, III. 1987. Whipple’s disease. Charles C Thomas, Publisher, Springfield, IL.
  2. 2.0 2.1 Biagi, F.; Balduzzi, D.; Delvino, P.; Schiepatti, A.; Klersy, C.; Corazza, G. R. (2015). "Prevalence of Whipple's disease in north-western Italy". European Journal of Clinical Microbiology & Infectious Diseases. 34 (7): 1347–1348. doi:10.1007/s10096-015-2357-2. ISSN 0934-9723.
  3. Durand DV, Lecomte C, Cathébras P, Rousset H, Godeau P (1997). "Whipple disease. Clinical review of 52 cases. The SNFMI Research Group on Whipple Disease. Société Nationale Française de Médecine Interne". Medicine (Baltimore). 76 (3): 170–84. PMID 9193452.
  4. Marth, Thomas; Raoult, Didier (2003). "Whipple's disease". The Lancet. 361 (9353): 239–246. doi:10.1016/S0140-6736(03)12274-X. ISSN 0140-6736.
  5. 5.0 5.1 Marth, Thomas (2015). "Tropheryma whipplei, Immunosuppression and Whipple's Disease: From a Low-Pathogenic, Environmental Infectious Organism to a Rare, Multifaceted Inflammatory Complex". Digestive Diseases. 33 (2): 190–199. doi:10.1159/000369538. ISSN 0257-2753.
  6. Dolmans, Ruben A. V.; Boel, C. H. Edwin; Lacle, Miangela M.; Kusters, Johannes G. (2017). "Clinical Manifestations, Treatment, and Diagnosis of Tropheryma whipplei Infections". Clinical Microbiology Reviews. 30 (2): 529–555. doi:10.1128/CMR.00033-16. ISSN 0893-8512.
  7. Fenollar, Florence; Puéchal, Xavier; Raoult, Didier (2007). "Whipple's Disease". New England Journal of Medicine. 356 (1): 55–66. doi:10.1056/NEJMra062477. ISSN 0028-4793.
  8. Fenollar, Florence; Laouira, Sonia; Lepidi, Hubert; Rolain, Jean‐Marc; Raoult, Didier (2008). "Value ofTropheryma whippleiQuantitative Polymerase Chain Reaction Assay for the Diagnosis of Whipple Disease: Usefulness of Saliva and Stool Specimens for First‐Line Screening". Clinical Infectious Diseases. 47 (5): 659–667. doi:10.1086/590559. ISSN 1058-4838.
  9. Fenollar, Florence; Trani, Michèle; Davoust, Bernard; Salle, Bettina; Birg, Marie‐Laure; Rolain, Jean‐Marc; Raoult, Didier (2008). "Prevalence of AsymptomaticTropheryma whippleiCarriage among Humans and Nonhuman Primates". The Journal of Infectious Diseases. 197 (6): 880–887. doi:10.1086/528693. ISSN 0022-1899.
  10. Keita, Alpha Kabinet; Raoult, Didier; Fenollar, Florence (2013). "Tropheryma whippleias a commensal bacterium". Future Microbiology. 8 (1): 57–71. doi:10.2217/fmb.12.124. ISSN 1746-0913.
  11. Small, Pamela L.; Keita, Alpha Kabinet; Dubot-Pérès, Audrey; Phommasone, Koukeo; Sibounheuang, Bountoy; Vongsouvath, Manivanh; Mayxay, Mayfong; Raoult, Didier; Newton, Paul N.; Fenollar, Florence (2015). "High Prevalence of Tropheryma whipplei in Lao Kindergarten Children". PLOS Neglected Tropical Diseases. 9 (2): e0003538. doi:10.1371/journal.pntd.0003538. ISSN 1935-2735.
  12. Vinnemeier CD, Klupp EM, Krumkamp R, Rolling T, Fischer N, OwusuDabo E, Addo MM, Adu-Sarkodie Y, Kasmaier J, Aepfelbacher M, Cramer JP, May J, Tannich E. 2016. Tropheryma whipplei in children with diarrhoea in rural Ghana. Clin Microbiol Infect 22:65.e1– 65.e3

Template:WH Template:WS